Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Urges Pro-Rata Delay, Says 80% Of OPPS Claims Data Is Missing

This article was originally published in The Gray Sheet

Executive Summary

CMS should delay a pro-rata reduction on pass-through payments for devices under the outpatient prospective payment system (OPPS) because nearly 80% of its claims data is unnaccounted for, AdvaMed asserts in its most recent attempt to prevent the agency from making the cuts in 2002.

You may also be interested in...



CMS Should Shift 75% Of Pass-Through Costs To APCs - AdvaMed

By moving at least 75% of device costs from "pass-through" payments to the base ambulatory payment classification (APC) rates, the Centers for Medicare & Medicaid Services can soften the impact of future pro-rata cuts, according to AdvaMed.

CMS Should Shift 75% Of Pass-Through Costs To APCs - AdvaMed

By moving at least 75% of device costs from "pass-through" payments to the base ambulatory payment classification (APC) rates, the Centers for Medicare & Medicaid Services can soften the impact of future pro-rata cuts, according to AdvaMed.

Medicare Contractor Reform Will Preserve "Localized Trends," Scully Says

Local decision-making on Medicare coverage issues will remain uncompromised by efforts to reform contracting policy, Centers for Medicare & Medicaid Services Administrator Tom Scully assured lawmakers Sept. 25.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel